Pengaruh Pemberian Curcumin terhadap Perbaikan Gejala Klinis pada Pasien Tuberkulosis dalam Pengobatan Kategori 1 Fase Intensif

Rima Mellia; Fajrinur Syarani; Parluhutan Siagian; Putri Chairani Eyanoer

doi:10.55606/termometer.v4i4.7091

Authors

Rima Mellia Universitas Sumatera Utara
Fajrinur Syarani Universitas Sumatera Utara
Parluhutan Siagian Universitas Sumatera Utara
Putri Chairani Eyanoer Universitas Sumatera Utara

DOI:

https://doi.org/10.55606/termometer.v4i4.7091

Keywords:

Antituberculosis Treatment, Clinical Symptoms, Curcuma, Pulmonary Tuberculosis, Tuberculosis

Abstract

Tuberculosis (TB) can cause respiratory and systemic symptoms. Respiratory symptoms include persistent cough for more than three weeks, hemoptysis, shortness of breath, and chest discomfort, while systemic manifestations include fever, malaise, night sweats, decreased appetite, and weight loss. In patients with pulmonary tuberculosis undergoing antituberculosis treatment (ATT), these manifestations are expected to gradually improve, particularly during the first two months of treatment. This study aimed to determine the contribution of Curcuma supplementation to the improvement of clinical manifestations in patients with pulmonary tuberculosis after completing the two-month intensive phase of treatment. This experimental study was conducted from April to June 2019 and involved 100 patients with pulmonary tuberculosis who were divided into intervention and control groups. The intervention group received Curcuma once daily for two months, while the control group received no supplementation. Patients’ clinical conditions were assessed before and after the intensive phase and analyzed using the Chi-Square test with SPSS. The results showed no significant difference in the improvement of clinical symptoms between the Curcuma and control groups. Thus, Curcuma supplementation was not significantly associated with improvements in clinical signs and symptoms during the intensive phase of ATT.

Downloads

Download data is not yet available.

References

Amin, Z., & Bahar, S. (2025). Tuberkulosis paru. In A. W. Sudoyo, B. Setiyohadi, & I. Alwi (Eds.), Buku ajar ilmu penyakit dalam.

Badan Pusat Statistik. (2017). Statistik kesejahteraan rakyat 2017. Badan Pusat Statistik.

Bai, X., et al. (2016). Curcumin enhances human macrophage control of Mycobacterium tuberculosis infection. Respirology, 21(5), 951–957. https://doi.org/10.1111/resp.12762

Brinkevich, S. D., Ostrovskaya, N. I., Parkhach, M. E., Samovich, S. N., & Shadyro, O. I. (2022). Effects of curcumin and related compounds on processes involving alpha-hydroxyethyl radicals. Free Radical Research, 46, 295–302. https://doi.org/10.3109/10715762.2011.653966

Byrne, J. A., Strautnieks, S. S., & Mieli-Vergani, G. B. B. (2012). Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clinical and Experimental Pharmacology and Physiology, 39, 283–299. https://doi.org/10.1111/j.1440-1681.2011.05648.x

Kementerian Kesehatan Republik Indonesia. (2015). Survei prevalensi tuberkulosis 2013–2014. Kementerian Kesehatan Republik Indonesia.

Kementerian Kesehatan Republik Indonesia. (2016). National strategic plan of tuberculosis control 2016–2020. Kementerian Kesehatan Republik Indonesia.

Kim, S. R., Park, H. J., Bae, Y. H., Ahn, S. C., Wee, H. J., Yun, I., Jang, H. O., Bae, M. K., & Bae, S. K. (2012). Curcumin down-regulates visfatin expression and inhibits breast cancer cell invasion. Endocrinology, 153, 554–563. https://doi.org/10.1210/en.2011-1413

Kumari, B., Kumar, T., & Kaur, V. (2018). Hepatoprotective effect of ethanolic extract of Curcuma longa Linn. on antitubercular drugs induced hepatotoxicity in albino rats. International Research Journal of Pharmacy, 9, 106–110. https://doi.org/10.7897/2230-8407.0910235

Mary Helen, P. A., Susheela, G. K., Jayasree, S., Nizzy, A. M., Rajagopal, B., & Jeeva, S. (2012). Phytochemical characterization and antimicrobial activity of Curcuma xanthorrhiza Roxb. Asian Pacific Journal of Tropical Biomedicine, 2, S637–S640. https://doi.org/10.1016/S2221-1691(12)60288-3

Mason, R. J., Murray, J. F., Broaddus, V. C., Nadel, J. A., Martin, T. R., & Talmadge, E. (Eds.). (2016). Murray and Nadel's textbook of respiratory medicine (6th ed.). Elsevier.

Mitchell, J. R., Zimmerman, H. J., & Ishak, K. G. (1976). Isoniazid liver injury: Clinical spectrum, pathology, and probable pathogenesis. Annals of Internal Medicine, 84, 181–192. https://doi.org/10.7326/0003-4819-84-2-181

Moon, H. J., Ko, W. K., Han, S. W., Kim, D. S., Hwang, Y. S., Park, H. K., & Kwon, I. K. (2012). Antioxidants, like coenzyme Q10, selenite, and curcumin, inhibited osteoclast differentiation by suppressing reactive oxygen species generation. Biochemical and Biophysical Research Communications, 418, 247–253. https://doi.org/10.1016/j.bbrc.2012.01.005

Noorafshan, A., & Ashkani-Esfahani, S. (2013). A review of therapeutic effects of curcumin. Current Pharmaceutical Design, 19(11), 2032–2046. https://doi.org/10.2174/138161213805289273

Pandey, A., Gupta, R. K., Bhargava, A., & Agrawal, B. (2011). Antibacterial activities of curcumin bioconjugates. International Journal of Pharmacology, 7, 874–879. https://doi.org/10.3923/ijp.2011.874.879

Peraturan Menteri Kesehatan Republik Indonesia Nomor 67 Tahun 2016 tentang Penanggulangan Tuberkulosis. (2016).

Peraturan Presiden Republik Indonesia Nomor 59 Tahun 2017 tentang Pelaksanaan Pencapaian Tujuan Pembangunan Berkelanjutan. (2017).

Pusat Data dan Informasi Kementerian Kesehatan Republik Indonesia. (2018). Pusdatin tuberkulosis 2018: TOSS TB dicari para pemimpin untuk dunia bebas TBC. Kementerian Kesehatan Republik Indonesia.

Ramappa, V., & Aithal, G. P. (2013). Hepatotoxicity related to anti-tuberculosis drugs: Mechanisms and management. Journal of Clinical and Experimental Hepatology, 3(1), 37–49. https://doi.org/10.1016/j.jceh.2012.12.001

Rasad, S. (2016). Tuberkulosis paru. In S. Rasad (Ed.), Radiologi diagnostik (2nd ed., pp. 131–144). Badan Penerbit FKUI.

Sarma, G. R., Immanuel, C., & Kailasam, S. (1986). Rifampin-induced release of hydrazine from isoniazid: A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin. American Review of Respiratory Disease, 133, 1072–1075.

Sherwood, L. (2022). Fisiologi manusia dari sel ke sistem (6th ed.). EGC.

Shin, S. K., Ha, T. Y., McGregor, R. A., & Choi, M. S. (2011). Long-term curcumin administration protects against atherosclerosis via hepatic regulation of lipoprotein cholesterol metabolism. Molecular Nutrition & Food Research, 55, 1829–1840. https://doi.org/10.1002/mnfr.201100440

Simadibrata, K. M., & Setiati, S. (2021). Buku ajar ilmu penyakit dalam (Jilid II, 4th ed.). Pusat Penerbitan Departemen Ilmu Penyakit Dalam FKUI.

Singanayagam, A., et al. (2012). A comparison between two strategies for monitoring hepatic function during antituberculous therapy. American Journal of Respiratory and Critical Care Medicine, 185(6), 653–659. https://doi.org/10.1164/rccm.201105-0850OC

Tyagi, P., Singh, M., Kumari, H., Kumari, A., & Mukhopadhyay, K. (2015). Bactericidal activity of curcumin is associated with damaging of bacterial membrane. PLoS ONE, 10, e0121313. https://doi.org/10.1371/journal.pone.0121313

Wahyudi, A. D., & Soedarsono. (2015). Farmakogenomik hepatotoksisitas obat anti tuberkulosis. Jurnal Respirasi, 1(3), 103–108. https://doi.org/10.20473/jr.v1-I.3.2015.103-108

World Health Organization. (2017). Global tuberculosis report 2017. World Health Organization. https://www.who.int/gho/mortality_burden_disease/cause-death/top/en/